Getting Mounjaro specifically for weight loss is complicated because the drug is only FDA-approved for type 2 diabetes. The same active ingredient, tirzepatide, is sold under a different brand name, Zepbound, for weight management. Understanding this distinction is the key to navigating prescriptions, insurance, and cost.
Mounjaro and Zepbound Are the Same Drug
Mounjaro and Zepbound contain the identical molecule: tirzepatide, made by Eli Lilly. The company intentionally created two separate brands to match two different FDA approvals. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition like high blood pressure, high cholesterol, or sleep apnea.
This matters because if your goal is weight loss and you don’t have type 2 diabetes, Zepbound is the on-label prescription. Asking for Mounjaro “off-label” for weight loss creates insurance and coverage problems that are largely avoidable by simply requesting the correct brand.
Who Qualifies for a Prescription
To get tirzepatide prescribed for weight loss (as Zepbound), you generally need to meet one of two criteria. The first is a BMI of 30 or above, which qualifies on its own. The second is a BMI between 27 and 30 combined with at least one weight-related health condition. Qualifying conditions include high blood pressure, abnormal cholesterol, obstructive sleep apnea, cardiovascular disease, or prediabetes.
Your prescriber will also expect you to combine the medication with a reduced-calorie diet and increased physical activity. Tirzepatide is approved as an add-on to lifestyle changes, not a replacement for them. If you have type 2 diabetes and want weight loss benefits, Mounjaro is the appropriate prescription since it treats your diabetes while also producing significant weight reduction.
How the Drug Works
Tirzepatide activates two hormone receptors in your body at once: GIP and GLP-1. Most other weight loss injections, like semaglutide (Wegovy/Ozempic), only target GLP-1. The dual action is what sets tirzepatide apart. GLP-1 activation slows stomach emptying and reduces appetite signals in the brain. GIP activation appears to independently improve how your body responds to insulin, through a mechanism separate from weight loss itself.
In the landmark SURMOUNT-1 trial, people without diabetes who took tirzepatide for 72 weeks lost an average of 15% of their body weight on the lowest dose (5 mg), 19.5% on the middle dose (10 mg), and 20.9% on the highest dose (15 mg). The placebo group lost 3.1%. For someone weighing 250 pounds, the highest dose translates to roughly 52 pounds lost over about a year and a half.
Where to Get a Prescription
You have two main routes: your existing doctor or a telehealth provider that specializes in weight management.
Your primary care doctor or an endocrinologist can prescribe tirzepatide if you meet the criteria. This is often the simplest path if you already have an established relationship and your doctor is comfortable prescribing weight management medications. Bring up the conversation directly. Many doctors are now familiar with these drugs and willing to prescribe them.
If your doctor is reluctant or you’d prefer a more streamlined process, telehealth platforms offer consultations specifically for obesity treatment. Eli Lilly highlights several independent virtual care options on its website, including Form Health, 9amHealth, and knownwell. These platforms pair you with providers who specialize in weight management, often include dietitian support, and can prescribe medication after a virtual evaluation. Most accept commercial insurance, and some accept Medicare or Medicaid. All offer self-pay options as well. These are far from the only choices. Dozens of telehealth weight loss clinics now offer tirzepatide consultations.
One thing to watch for: some telehealth platforms previously prescribed compounded versions of tirzepatide (copies made by compounding pharmacies during the drug shortage). As of early 2025, tirzepatide no longer appears on the FDA’s drug shortage list, which limits the legal basis for compounding. Make sure any prescription you receive is for the brand-name product from a licensed pharmacy.
What It Costs Without Insurance
The list price for Mounjaro is $1,112.16 for a one-month supply (four pens). Zepbound is priced similarly. This is what you can expect to pay out of pocket if you have no insurance coverage and no discount programs.
Eli Lilly offers a savings card that can bring the cost down to $25 for a one-month or three-month prescription. The catch is that this card typically requires commercial insurance that already covers the drug. If your insurance doesn’t cover it or you’re uninsured, the savings card may not apply.
For people paying cash, prescription discount websites sometimes offer coupons that reduce the price below the list amount, though these can’t be combined with insurance benefits. It’s worth comparing prices across pharmacies, as the actual cash price varies.
Navigating Insurance Coverage
Insurance is the biggest hurdle for most people. Coverage varies widely by plan, and many insurers still exclude weight management medications entirely. Here’s what to expect.
If you have type 2 diabetes and your doctor prescribes Mounjaro, insurance is more likely to cover it because it’s being used for its approved indication. Weight loss in this case is a beneficial side effect of a diabetes medication.
If you don’t have diabetes and want tirzepatide for weight loss, you need Zepbound prescribed under its weight management indication. Many commercial plans now cover it, but most require prior authorization. This means your doctor submits documentation proving you meet the BMI and health criteria. Some plans also require evidence that you’ve tried other weight loss approaches first, like behavioral programs or older medications.
Using Mounjaro off-label for weight loss (instead of Zepbound) is a common reason claims get denied. Insurance systems flag the mismatch between the drug’s approved use and the diagnosis code on the prescription. Some prior authorization forms explicitly ask whether Mounjaro is being prescribed for weight management, and if the answer is yes, the request is automatically rejected. This is why the Mounjaro-versus-Zepbound distinction isn’t just academic: it directly affects whether your insurance will pay.
If your claim is denied, you can appeal. Your doctor can submit a letter of medical necessity explaining why the medication is appropriate for you. Success rates on appeal vary, but it’s always worth trying, especially if you have documented weight-related health conditions.
What to Expect After Starting
Tirzepatide is a once-weekly injection you give yourself, typically in the abdomen, thigh, or upper arm. You start at the lowest dose (2.5 mg) and increase gradually over several months. This stepwise approach helps your body adjust and reduces side effects. Most people reach their target dose within four to five months.
The most common side effects are nausea, diarrhea, and decreased appetite, particularly during dose increases. These tend to be mild to moderate and improve as your body adapts. Eating smaller meals and avoiding high-fat foods can help manage the nausea in the early weeks.
Weight loss typically begins within the first month but accelerates as the dose increases. Based on trial data, most of the weight loss occurs over the first 72 weeks, with results plateauing after that. The medication works best as a long-term treatment. People who stop taking it generally regain a significant portion of the weight, which is why prescribers typically discuss it as an ongoing commitment rather than a short-term fix.